DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 11 - 20 of 282

Investigator:Ruichen Han


Title:Functional connections in the hippocampus subregion of familial Alzheimer's disease before symptoms as biomarkers for predicting disease status

Date of Request:08/05/2023

Status:pending approval

ID:DIAN-D2316




Aim 1:To investigate whether there are differences in the damage patterns of brain functional network connections between familial Alzheimer's disease and sporadic Alzheimer's disease




Aim 2:To explore can functional connections serve as a biomarker to predict cognitive state







Investigator:Karin Meeker


Title:Tau Phosphorylation in Preclinical and Symptomatic Autosomal Dominant Alzheimer Disease

Date of Request:08/05/2023

Status:pending approval

ID:DIAN-D2317




Aim 1:Temporal progression of tauopathy. Tau sites (e.g., pT181, pT202, pT205, pT217) will be assessed in relation to preclinical AD biomarkers (e.g., CSF Ab42) and biomarkers of symptom onset (e.g., CSF total tau, RS-FC, cognitive performance), and EYO. Longitudinal changes in variables will also be plotted against EYO to determine temporal trajectories and to assess how biomarkers change relative to one another across disease progression. It is hypothesized that elevation of each site will occur at varying stages of the disease process and will follow distinct individual trajectories over time. Specifically, it is expected that relative to other tau sites, elevation in CSF pT217 and pT181 levels will arise first and will most strongly associate with preclinical biomarkers, such as CSF Ab42, while other tau sites will become elevated later in the disease process and will most strongly associate with biomarkers of symptom onset.




Aim 2:Spatial progression of tauopathy in ADAD. Compared to established biomarkers (e.g., amyloid and total tau), it is unknown how phosphorylated tau sites differentially relate to and drive alterations in resting state brain network dynamics during the preclinical and clinical phases of ADAD. To determine whether specific tau sites are associated with alterations in brain network RS-FC organization, tau sites will be cross-sectionally correlated with within-network and between-network RS-FC. Longitudinal changes in tau sites and RS-FC will additionally be correlated and plotted against EYO to determine whether changes in tau sites and RS-FC arise in a specific pattern, and more specifically to elucidate the spatial progression of tauopathy. It is hypothesized that elevated levels of CSF tau sites will be associated with a local to diffuse pattern of decreases in RS-FC, and that associations between tau sites and RS-FC will be greatest in regions where tau deposition occurs, as measured by tau positron emission tomography (PET).







Investigator:Wencai Ding, Huan He.


Title:Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in Dominantly Inherited Alzheimer’s disease.

Date of Request:07/25/2023

Status:pending approval

ID:DIAN-D2315




Aim 1:We aimed to study the cortical and subcortical microstructural variations using surface-based analysis (cMD and cortical fractional anisotropy (cFA)) and TBSS (MD and FA)




Aim 2:We also explored the relationships between multimodal macrostructural/ microstructural measures and the clinical scale scores representing language abilities (verbal fluency test (VFT) and Boston naming test (BNT)).







Investigator:song weihong


Title:Study the relationship between Glymphatic function, Aβ protein and cognitive decline in autosomal dominant Alzheimer disease.

Date of Request:07/25/2023

Status:pending approval

ID:DIAN-D2314




Aim 1:To assess the glymphatic function in mutation carriers and non-carriers




Aim 2:Examine the relationship between Glymphatic function, Aβ protein and cognitive decline in autosomal dominant Alzheimer disease.







Investigator:Giuseppe Barisano


Title:Evaluating the Role of Perivascular Spaces and White Matter Hyperintensities in Dominantly Inherited Alzheimer's Disease and their Relationship with Amyloid and Tau

Date of Request:07/19/2023

Status:pending approval

ID:DIAN-D2313




Aim 1:To assess the spatial distribution of v-PVS and WMH in mutation carriers vs. non-carriers




Aim 2:To assess the prevalence and severity of v-PVS and WMH in asymptomatic mutation carriers vs. non-carriers




Aim 3:To investigate the incidence of MRI-visible v-PVS and WMH in mutation carriers vs. non-carriers along the disease trajectory and their relationship with the incidence of amyloid and tau




Aim 4To investigate the spatial relationship between v-PVS/WMH and amyloid/tau accumulation using a disconnectomics approach

Investigator:Matthew Dean


Title:Assessment of Basal Forebrain degeneration using MRI in Alzheimer's Disease

Date of Request:07/06/2023

Status:pending approval

ID:DIAN-D2312




Aim 1:To determine the pattern of basal forebrain measured by MRI degeneration in familial Alzheimer's disease and relationships with biomarkers




Aim 2:To compare the pattern of basal forebrain degeneration measured by MRI in familial Alzheimer's disease to sporadic disease







Investigator:Beau Ances


Title:Comparison of Astrocyte-related Markers in Down Syndrome and Autosomal-Dominant Alzheimer Disease Using the Amyloid- Tau-Neurodegeneration (AT(N)) Framework

Date of Request:06/30/2023

Status:pending approval

ID:DIAN-D2311




Aim 1:Evaluate and compare the association between plasma GFAP and imaging measures of AD in Down syndrome and ADAD.










Investigator:Cyril Pottier


Title:Modifiers of Alzheimer's disease: a genetic approach

Date of Request:04/28/2023

Status:pending

ID:DIAN-D2310




Aim 1:To identify genetic modifiers of disease presentation in PSEN1 mutation carriers










Investigator:Dr. Tallulah Andrews


Title:Single-nucleus RNAseq of a humanized mouse model of Alzheimer's disease

Date of Request:04/24/2023

Status:pending approval

ID:DIAN- D2309




Aim 1:Generate a novel humanized mouse model of AD with disease variants in APP and APOE genes.




Aim 2:Perform deep behavioural and molecular phenotyping of the mouse model




Aim 3:Perform snRNAseq of multiple brain regions of mouse model and compare to human snRNAseq from patients with AD




Investigator:Nelly Joseph-Mathurin


Title:Evaluation of the neurovascular unit in the setting of pathogenesis and treatment of autosomal dominant Alzheimer disease

Date of Request:04/21/2023

Status:approved

ID:DIAN-D2308




Aim 1:Perform proteomic characterization of NVU disruption and develop imaging markers of vascular changes in ADAD.




Aim 2:Determine the trajectories of NVU disruption markers and their relation to the pattern of disease progression in ADAD.




Aim 3:Examine influence of NVU disruption on drug efficacy and safety outcome measures in ADAD.